The anti-fibrotic effects of microRNA-153 by targeting TGFBR-2 in pulmonary fibrosis

被引:39
|
作者
Liang, Chunlian [1 ]
Li, Xiuli [1 ]
Zhang, Lin [1 ]
Cui, Dajiang [1 ]
Quan, Xiaojuan [1 ]
Yang, Weilin [1 ]
机构
[1] Xi An Jiao Tong Univ, Affiliated Hosp 2, Dept Geriatr, Sch Med, Xian 710004, Shaanxi, Peoples R China
关键词
miR-153; TGF-beta; TGFBR2; Idiopathic pulmonary fibrosis; EPITHELIAL-MESENCHYMAL TRANSITION; GROWTH-FACTOR-BETA; LUNG FIBROSIS; EXTRACELLULAR-MATRIX; LATENT TGF-BETA-1; FIBROBLASTS; ACTIVATION; EXPRESSION; RECEPTORS; DIFFERENTIATION;
D O I
10.1016/j.yexmp.2015.07.011
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Idiopathic pulmonary fibrosis (IPF) is a progressive interstitial fibrotic lung disease with an undefined etiology and no effective treatments. By binding to cell surface receptors, transforming growth factor-beta (TGF-beta) plays a pivotal role in lung fibrosis. Therefore, the screening of microRNAs (miRNAs), especially those interrupting the effects of TGF-beta, may provide information not only on the pathomechanism, but also on the treatment of this disease. In the present study, we found that miR-153 expression was dysregulated in the lungs of mice with experimental pulmonary fibrosis and TGF-beta 1 decreased miR-153 expression in pulmonary fibroblasts. Moreover, increased miR-153 levels attenuated, whereas the knock down of miR-153 promoted the pro-fibrogenic activity of TGF-beta 1, and miR-153 reduced the contractile and migratory activities of fibroblasts. In addition, TGFBR2, a transmembrane serine/threonine kinase receptor for TGF-beta, was identified as a direct target of miR-153. Furthermore, by post-transcriptional regulation of the expression of TGEBR2, phosphorylation of SMAD2/3 was also influenced by miR-153. These data suggest that miR-153 disturbs TGF-beta 1 signal transduction and its effects on fibroblast activation, acting as an anti-fibrotic element in the development of pulmonary fibrosis. (C) 2015 Elsevier Inc. All rights reserved.
引用
收藏
页码:279 / 285
页数:7
相关论文
共 50 条
  • [31] Anti-fibrotic efficacy of nintedanib in pulmonary fibrosis via the inhibition of fibrocyte activity
    Seidai Sato
    Shintaro Shinohara
    Shinya Hayashi
    Shun Morizumi
    Shuichi Abe
    Hiroyasu Okazaki
    Yanjuan Chen
    Hisatsugu Goto
    Yoshinori Aono
    Hirohisa Ogawa
    Kazuya Koyama
    Haruka Nishimura
    Hiroshi Kawano
    Yuko Toyoda
    Hisanori Uehara
    Yasuhiko Nishioka
    Respiratory Research, 18
  • [32] Real-life survival of idiopathic pulmonary fibrosis with anti-fibrotic medication
    Bleinc, Alexandre
    Blin, Timothee
    Legue, Sylvie
    Mankikian, Julie
    Plantier, Laurent
    Marchand-Adam, Sylvain
    REVUE DES MALADIES RESPIRATOIRES, 2023, 40 (05) : 371 - 381
  • [33] Tolerability and safety of anti-fibrotic agents for idiopathic pulmonary fibrosis in real world
    Sugimoto, Chikatoshi
    Inoue, Yoshikazu
    Arai, Toru
    Kasai, Takehiko
    Akira, Masanori
    Hayashi, Seiji
    Tachibana, Kazunobu
    Sasaki, Yumiko
    Takeuchi, Naoko
    Minomo, Syojiro
    Ikegami, Naoya
    EUROPEAN RESPIRATORY JOURNAL, 2017, 50
  • [34] Olodaterol shows anti-fibrotic efficacy in in vitro and in vivo models of pulmonary fibrosis
    Herrmann, Franziska Elena
    Wollin, Lutz
    Wirth, Johannes
    Gantner, Florian
    Laemmle, Baerbel
    Wex, Eva
    BRITISH JOURNAL OF PHARMACOLOGY, 2017, 174 (21) : 3848 - 3864
  • [35] GED-0507 as a novel anti-fibrotic treatment option for pulmonary fibrosis
    Speca, Silvia
    Dubuquoy, Caroline
    Rousseaux, Christel
    Jadot, Elodie
    Desreumaux, Pierre
    Spagnolo, Paolo
    EUROPEAN RESPIRATORY JOURNAL, 2018, 52
  • [36] Anti-fibrotic efficacy of nintedanib on pulmonary fibrosis via suppression of fibrocyte activity
    Morizumi, Shun
    Sato, Seidai
    Abe, Shuichi
    Okazaki, Hiroyasu
    Chen, Yanjuan
    Goto, Hisatsugu
    Aono, Yoshinori
    Ogawa, Hirohisa
    Hanibuchi, Masaki
    Uehara, Hisanori
    Nishioka, Yasuhiko
    EUROPEAN RESPIRATORY JOURNAL, 2016, 48
  • [37] Outcome of lung transplantation in idiopathic pulmonary fibrosis with previous anti-fibrotic therapy
    Leuschner, Gabriela
    Stocker, Florian
    Veit, Tobias
    Kneidinger, Nikolaus
    Winter, Hauke
    Schramm, Rene
    Weig, Thomas
    Matthes, Sandhya
    Ceelen, Felix
    Arnold, Paola
    Munker, Dieter
    Klenner, Friederike
    Hatz, Rudolf
    Frankenberger, Marion
    Behr, Juergen
    Neurohr, Claus
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2018, 37 (02): : 268 - 274
  • [38] Anti-fibrotic therapy and lung transplant outcomes in patients with idiopathic pulmonary fibrosis
    Astor, Todd L. L.
    Goldberg, Hilary J. J.
    Snyder, Laurie D. D.
    Courtwright, Andrew
    Hachem, Ramsey
    Pena, Tahuanty
    Zaffiri, Lorenzo
    Criner, Gerard J. J.
    Budev, Marie M. M.
    Thaniyavarn, Tany
    Leonard, Thomas B. B.
    Bender, Shaun
    Barakat, Aliaa
    Breeze, Janis L. L.
    LaCamera, Peter
    THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2023, 17
  • [39] Real-World Tolerability Of Anti-Fibrotic Therapy For Idiopathic Pulmonary Fibrosis
    Kaur, R.
    King, C.
    Brown, A.
    Shlobin, O.
    Ahmad, S.
    Weir, N.
    Nathan, S. D.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195
  • [40] Prognosis of idiopathic pulmonary fibrosis without anti-fibrotic therapy: a systematic review
    Khor, Yet H.
    Ng, Yvonne
    Barnes, Hayley
    Goh, Nicole S. L.
    McDonald, Christine F.
    Holland, Anne E.
    EUROPEAN RESPIRATORY REVIEW, 2020, 29 (157): : 1 - 16